Novartis announces tislelizumab efficacy results from phase 3 trial
Tislelizumab shows favourable safety profile compared to sorafenib among liver cancer patients
Read More
Author: John Pinching
Stada launches prostate cancer treatment across 21 European countries
Company is introducing abiraterone film-coated tablets for treating metastatic prostate cancer
Read More
Positive phase 3 data for Sanofi’s Dupixent
Research showed significant improvements in signs and symptoms of prurigo nodularis
Read More
Individuals Marketer of the Year 2022 categories still open!
You can still submit your entry before the imminent 16 September 2022 deadline – but hurry!
Read More
Still time to enter the 2022 Sales Awards!
Get started on your entry for these prestigious awards now – the deadline is 16 September 2022
Read More- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
- ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
